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INTRODUCTION
Several organizations have published guidelines for 
imaging diagnosis of hepatocellular carcinoma (HCC), 
including the American Association for the Study of Liver 
Diseases (AASLD), European Association for the Study 
of the Liver–European Organization for Research and 
Treatment of Cancer (EASL-EORTC), Asian-Pacific Association 
for the Study of the Liver (APASL), Korean Liver Cancer 
Study Group-National Cancer Center (KLCSG-NCC), Japan 
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Society of Hepatology (JSH), and American College of 
Radiology Liver Imaging Reporting and Data Systems (LI-
RADS) (1-5). Because the diagnostic criteria of HCC are 
mainly based on its hemodynamic hallmarks, which include 
hyperenhancement and washout in the hepatic arterial 
and venous phases, respectively, these guidelines were 
established based on the assumption of dynamic computed 
tomography (CT) or magnetic resonance imaging (MRI) with 
extracellular contrast media (ECCM) being the first-line 
modality.
Since its initial approval in 2004, gadoxetic acid 
(gadolinium ethoxybenzyl diethylenetriamine pentaacetic 
acid or gadoxetate disodium) has been increasingly used as 
a contrast agent, especially in Asia and Europe. A survey in 
2016 revealed 177 of 195 (90.7%) members of the Korean 
Society of Abdominal Radiology (KSAR) as using gadoxetic 
acid for MRI in patients with suspected HCC. Several studies 
have demonstrated the clinical efficacy of gadoxetic acid in 
early detection of HCC by providing functional information 
as a hepatocyte-specific contrast agent as well as 
hemodynamic information. Although ECCMs and gadoxetic 
acid are both gadolinium-based contrast agents, they differ 
in terms of pharmacokinetic characteristics, dosage, and 
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mechanism of action.
The regional heterogeneity of HCC in demographic 
characteristics, prevalence, surveillance, and socioeconomic 
status necessitates different treatment approaches, 
leading to variations in survival outcomes, which affects 
the diagnostic strategy. Korea has a few unique situations 
which have steered clinicians towards application of 
gadoxetic acid-enhanced MRI for early diagnosis of HCC; the 
highest prevalence of HCC, hepatitis B-related chronic liver 
disease as the most common underlying etiology, variable 
curative treatment options–especially hepatic resection 
or radiofrequency ablation–for early HCC, and affordable 
treatment because of the national health insurance system. 
However, diagnosis of HCC by gadoxetic acid-enhanced liver 
MRI poses certain challenges beyond the scope of current 
guidelines. Therefore, the KSAR organized meetings to reach 
a consensus on guidelines for diagnosis of HCC by gadoxetic 
acid-enhanced MRI with updated perspectives and in 
consideration of current medical practices in Korea.
MATERIALS AND METHODS
Five organizing members (M. S. P., J. Y. C., S. Y. K., J. M. 
L., and Y. K. K.) performed literature review in consensus to 
collect data regarding diagnosis of HCC by gadoxetic acid-
enhanced MRI. The PubMed and MEDLINE databases were 
searched for relevant original articles, systematic reviews/
meta-analyses, and consensus statement/guidelines in 
English. These data were used to extract relevant topics 
to be addressed in a questionnaire. Debatable issues 
that were deemed essential for diagnosis of HCC by 
gadoxetic acid-enhanced MRI were catalogued. Four panels 
comprising twenty-one panelists–all members of the KSAR 
and leading abdominal radiologists with expertise in the 
field of liver MRI–were each assigned one or two issues 
of debate. An internist (D. Y. K.), a pathologist (E. S. Y.), 
and two additional abdominal radiologists (M. J. K. and 
W. J. L.) were invited as advising members. These panels 
consolidated relevant evidences regarding their assigned 
issues and prepared a draft of a specific questionnaire, 
along with a summary of the clinical and scientific rationale 
behind their suggestions. The questionnaire was drafted at 
a face-to-face meeting and refined by online discussion.
The initial 34 questions were presented to members of 
the KSAR at a one-day symposium (5th Liver Imaging Day; 
KSAR-Consensus on Diagnosis of HCC with Gadoxetic Acid-
enhanced MRI) on April 16, 2016, which involved didactic 
lectures and a thorough discussion on the issues of debate. 
A total of 195 board-certified radiologists specializing 
in abdominal radiology attended this symposium, where 
the questionnaire was put through first-round voting. 
The proposed consensus statement was developed using a 
modified Delphi method based on a six-point scale: strongly 
agree, agree with minor reservation, agree with major 
reservation, disagree with minor reservation, disagree with 
major reservation, and strongly disagree. Consensus was 
predefined at ≥ 80% of the sum of votes indicating strong 
agreement or agreement with minor reservation. Of the 
34 questionnaire items, 16 achieved consensus. Following 
the first-round vote, the questionnaire was refined by the 
panelists by online discussion and put through second-
round voting at a half-day satellite conference, attended by 
128 board-certified radiologists specializing in abdominal 
radiology, during the 39th Scientific Assembly and Annual 
Meeting of the KSAR, May 14, 2016. Finally, 12 of 16 
statements reached the 80% consensus threshold (Table 1). 
All votes were recorded by secret ballot.
Strategy for Diagnosis of HCC
Hepatocellular carcinoma can be diagnosed by 
histopathology or non-invasive imaging (6). In fact, HCC 
is the only malignancy for which pathologic confirmation 
is not mandatory for diagnosis. With advances in imaging 
techniques, reliable assessment can be made based on 
contrast-enhanced CT or MRI findings.
However, extensive geographical differences in tumor 
biology and regional tendencies make it challenging to 
establish universal guidelines for diagnosis of HCC. Moreover, 
guidelines are influenced by the clinical environment and 
resources available for treatment. The prevalence of HCC in 
Korea is higher compared to that in Western countries (7). 
Patients with positive imaging findings in high-prevalence 
populations are more likely to have HCC than those in low-
prevalence populations. Therefore, differences in disease 
prevalence might affect the likelihood of diagnosis. Choice 
of therapy is also influenced by regional and institutional 
tendencies (8). Because liver transplantation eliminates 
cancer as well as cirrhotic liver tissue, it is considered as the 
only curative treatment in many Western countries. While 
deceased donor-liver transplantation (DDLT) constitutes 
over 90% of liver transplantation cases in Western 
countries, most such cases in Korea involve living donor-
liver transplantation (9, 10). Since organ shortage remains 
a major limitation for DDLT, Western guidelines for imaging 
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diagnosis focus on achieving high specificity, comparable 
to that of histopathologic diagnosis, in order to maximize 
organ utilization. The United States Organ Procurement and 
Transplantation Network (OPTN) diagnostic criteria for HCC 
were specifically designed to improve specificity. In Korea, 
other treatment approaches, such as surgical resection, 
radiofrequency ablation, transcatheter arterial therapy, and 
systemic chemotherapy, are widely used for HCC. Given the 
vast differences in clinical environment between Western 
countries and Korea, diagnostic strategies for HCC also differ.
Despite controversies regarding its specificity, 
accumulating evidence shows that gadoxetic acid-enhanced 
MRI provides improved sensitivity for detecting HCC (11). 
In Asian countries where gadoxetic acid-enhanced MRI 
is widely used, diagnostic criteria for HCC are relaxed to 
increase sensitivity at the expense of specificity (12, 13). 
Corresponding with the emphasis on early detection, Asian 
guidelines have been developed to address early treatment. 
Because HCC frequently invades vessels and metastasizes 
to other parts of the liver and body, aggressive treatment 
of early-stage HCC improves long-term survival (14). A 
remaining issue is whether diagnostic sensitivity for HCC 
can be improved while maintaining acceptable specificity. 
Further studies are required to refine the current diagnostic 
criteria for HCC.
In the 2016 KSAR consensus meeting on diagnosis of HCC 
with gadoxetic acid-enhanced MRI, the consensus level for 
the following statement was 90%.
Table 1. Consensus Statements
Statement
Level of 
Agreement (%)
Noninvasive diagnostic criteria for HCC with gadoxetic acid-enhanced MRI should aim for early detection and high
  sensitivity, while maintaining acceptable specificity.
90.0
Definition of arterial-phase hyperenhancement should include hyperintensity relative to surrounding liver parenchyma
  in arterial-phase as well greater signal intensity in arterial phase in comparison with precontrast images (determined
  by subtraction imaging, when feasible).
91.2
In case of suboptimal gadoxetic acid-enhanced arterial-phase MR images, findings of recent CT arterial-phase images
  may be used. 
90.0
Dynamic CT images acquired within month of gadoxetic acid-enhanced MRI may be considered as appropriate substitutes
  for suboptimal arterial-phase gadoxetic acid-enhanced MR images.
88.0
Washout appearance should be determined on either portal venous or transitional phase of gadoxetic acid-enhanced MRI. 85.3
“Washout appearance” may be defined as hypointensity relative to background liver, regardless of arterial
  hyperenhancement in corresponding area. 
60.3
Sub-centimeter-sized HCC may be diagnosed by gadoxetic acid-enhanced liver MRI by applying additional refined
  diagnostic criteria in addition to typical vascular profile changes.
86.0
Additional diagnostic criteria include ancillary MRI findings such as restricted diffusion, mild to moderate hyperintensity
  on T2-weighted images, and hypointensity in hepatobiliary phase.
98.0
Nodules of sizes ranging from 1 to 2 cm and those of sizes > 2 cm do not require separate diagnostic criteria. 86.0
Mild to moderate hyperintensity on T2-weighted images and restricted diffusion may be considered ancillary features
  for differentiating HCCs from premalignant nodules.
74.0
In high-risk population, non-hypovascular HBP hypointense nodules, with ancillary features including mild to moderate
  hyperintensity on T2-weighted images and restricted diffusion, may be considered potentially malignant.
86.4
Strategies for diagnosis and management of non-hypovascular HBP hypointense nodules should vary according to
  previous or concomitant HCC. 
83.0
When optimal arterial-phase images cannot be obtained by gadoxetic acid-enhanced MRI, contrast-enhanced
  ultrasonography should be recommended for further characterization of non-hypovascular HBP hypointense nodules. 
26.0
Definition of capsular appearance on gadoxetic acid-enhanced MR images should be different from that on extracellular
  contrast media-based MR images.
85.3
“Capsular appearance” is better considered ancillary feature than major feature for diagnosis of HCC. 79.7
Impact of ancillary features on diagnosis of HCC should be clearly defined, and these features should be adapted
  for gadoxetic acid-enhanced MRI.
86.0
CT = computed tomography, HBP = hepatobiliary phase, HCC = hepatocellular carcinoma, MRI = magnetic resonance imaging
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Consensus Statement
Noninvasive diagnostic criteria for HCC with gadoxetic 
acid-enhanced MRI should aim for early detection and high 
sensitivity, while maintaining acceptable specificity.
Definition of Arterial-Phase Hyperenhancement
Arterial-phase hyperenhancement, a key imaging 
feature of HCC (2, 15), is observed in 76–82.7% of small 
HCCs and only 3.2–9.7% of benign nodules (16). It 
exhibits high positive predictive value (96.5–98.9%) and 
specificity (90.3–96.8%) but a low negative predictive 
value (54.6–62.5%) and moderate sensitivity (76–79.8%) 
(16). Therefore, acquisition of optimal late arterial-phase 
images is critical for noninvasive imaging diagnosis of HCC. 
Arterial-phase hyperenhancement on dynamic contrast-
enhanced MR images is generally defined as hyperintensity 
relative to the surrounding liver parenchyma in the arterial 
phase (16, 17). However, diagnosis based on this definition 
often leads to false-positive results in hepatic lesions that 
already exhibit hyperintensity on unenhanced T1-weighted 
images because of accumulation of fat, hemosiderin, 
glycoproteins, or copper (18, 19). Comparison of 
unenhanced and arterial-phase images is necessary to avoid 
this misinterpretation and detect arterial enhancement (20). 
However, in some instances, it is challenging to detect or 
determine arterial hyperenhancement by visually comparing 
two image sets. Additionally, because of the weak 
enhancement associated with small volumes of contrast 
media, low gadolinium concentrations (21), and acute 
transient dyspnea (11), suboptimal arterial enhancement is 
more frequent with gadoxetic acid-enhanced MRI than with 
ECCM-MRI. In such cases, subtraction images of unenhanced 
T1-weighted and arterial-phase images are helpful in 
detecting arterial-phase hyperenhancement (Fig. 1) (16, 22-
24). However, in subtraction imaging, image quality cannot 
be assured in case of misregistration due to patient-related 
or technical factors. Nevertheless, subtraction imaging 
has shown greater diagnostic accuracy than arterial-phase 
imaging and visual comparison of precontrast and arterial-
phase images (16). Therefore, when available, subtraction 
imaging is recommended for assessment of arterial-phase 
enhancement.
In the 2016 KSAR consensus meeting, the consensus level 
for the following statement was 91.2%.
Consensus Statement
Definition of arterial-phase hyperenhancement should 
include hyperintensity relative to the surrounding liver 
parenchyma in the arterial-phase as well greater signal 
intensity in the arterial phase in comparison with 
precontrast images (determined by subtraction imaging, 
when feasible).
Diagnosis Based on Recent CT Arterial-Phase Findings in 
Case of Suboptimal Gadoxetic Acid-Enhanced MR Images
Because of its higher relaxivity (25), the standard dosage 
of gadoxetic acid (0.025 or 0.1 mL/kg) (21, 26) is half in 
volume and a quarter in gadolinium concentration of the 
Fig. 1. HCC in 56-year-old man.
A. Pre-contrast T1-weighted image shows hyperintense nodule (arrow) in segment VI of liver. B. In arterial-phase of gadoxetic acid-enhanced 
magnetic resonance imaging, nodule (arrow) exhibits hyperintensity relative to surrounding liver parenchyma. C. Subtraction image obtained 
by subtracting pre-contrast-enhanced and arterial-phase T1-weighted images depicts true arterial enhancement of nodule (arrow). HCC = 
hepatocellular carcinoma
A B C
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general dosages of ECCMs. The lower dosage of gadoxetic 
acid in comparison with those of ECCMs results in a shorter 
bolus transit time and, thereby, a shorter late arterial-
phase window, which necessitates particular attention 
to the arterial-phase acquisition protocol. Additionally, 
intravenous gadoxetic acid administration is frequently 
associated with acute transient dyspnea, which results 
in severe motion artifacts in 12.9–18% of arterial-phase 
gadoxetic acid-enhanced MR images (11, 27, 28). These 
problems have been partially overcome by modification 
of contrast injection and imaging protocols, including a 
slower injection rate (1 mL/s rather than 2 mL/s) (29, 30), 
detection of arterial phase by test or fluoroscopic bolus 
monitoring rather than by fixed-scan delay (31, 32), and 
multiple short arterial-phase imaging (12, 33, 34). However, 
acquisition of optimal arterial-phase gadoxetic acid-
enhanced MR images is still challenging in clinical practice. 
As a practical solution for this issue, the LI-RADS (v2014) 
allows substitution of arterial-phase findings on suboptimal 
gadoxetic acid-enhanced MR images with those on recent 
CT images (35).
In the 2016 KSAR consensus meeting, the consensus 
levels for the following two statements were 90% and 88%, 
respectively.
Consensus statements
1. In case of suboptimal gadoxetic acid-enhanced 
arterial-phase MR images, the findings of recent CT arterial-
phase images may be used instead for diagnosis of HCC.
2. Dynamic CT images acquired within a month of 
gadoxetic acid-enhanced MRI may be considered as 
appropriate substitutes for suboptimal arterial-phase 
gadoxetic acid-enhanced MR images.
Appropriate Phase for Determining Washout Appearance
On ECCM-enhanced CT or MR images, the portal venous 
(PVP) or delayed phases (DP) are used to determine the 
presence of washout appearance (36). However, there is 
controversy regarding the most appropriate phase(s) of 
gadoxetic acid-enhanced MRI for evaluation of washout 
appearance (37, 38). Several latest guidelines that 
incorporate gadoxetic acid-enhanced MRI in the diagnostic 
algorithm for HCC permit different phases for identifying the 
washout pattern. The LI-RADS v2014 permits identification 
of washout appearance only in the PVP in order to maintain 
high specificity (5, 15). The KLCSG-NCC guidelines v2014 
permit identification of washout appearance in the PVP or 
transitional phase (TP; usually obtained around 3 minutes 
after contrast administration) (13). The consensus-based 
algorithm proposed by the Liver Cancer Study Group of 
Japan (LCSGJ) v2014 includes gadoxetic acid-enhanced MRI 
as a first-line imaging modality and permits identification 
of hypointensity in the TP and hepatobiliary phase (HBP) as 
an alternative to washout appearance for diagnosis of HCC 
after exclusion of hemangioma using other sequences of MRI 
and/or other imaging modalities (39). These discrepancies 
among different guidelines arise from individual preferences 
for higher sensitivity or specificity (40, 41), as mentioned 
in the “Strategy for the diagnosis of HCC”.
Hypointensity in the HBP is a useful feature for diagnosis 
of small HCCs, which might have influenced the LCSGJ to 
include the HBP for evaluation of washout appearance 
(42-44). However, most non-HCC malignancies and non-
hepatocyte-containing benign lesions and a proportion 
Fig. 2. HCC in 82-year-old man with chronic hepatitis C.
A-C. In gadoxetic acid-enhanced magnetic resonance images, 5-cm mass (arrows) exhibits arterial hyperenhancement (A), slight hyperintensity 
in portal venous phase (PVP) (B), and hypointensity in transitional phase (C). Washout appearance of nodule in PVP only might lead to 
false-negative diagnosis of HCC based on enhancement pattern. D. It (arrow) shows hypointensity on HBP. HBP = hepatobiliary phase, HCC = 
hepatocellular carcinoma
A B C D
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of borderline nodules (e.g., dysplastic nodules) show 
hypointensity in the HBP (36, 45, 46). Therefore, caution 
should be given in using hypointensity on the HBP as an 
alternative to washout appearance, since the former has 
been reported to result in substantially low specificity 
(< 50%) for detection of arterial-phase hyper-enhancing 
nodules of sizes ≥ 1 cm (47).
In comparison to multi-phasic CT, typical washout 
appearance of HCC on gadoxetic acid-enhanced MRI was less 
frequent if only PVP was used, while it was more frequent 
if PVP and/or TP was used (Fig. 2) (47, 48). However, the 
main concern regarding inclusion of the TP for determining 
washout appearance is that, the definition of hypointensity 
in the TP differs from that in the DP in ECCM-enhanced 
imaging. Since gadoxetic acid uptake by hepatocytes begins 
as early as the end of the PVP, hypointensity in the TP might 
be due to the combined effect of de-enhancement and lack 
of hepatocyte relative to the surrounding liver parenchyma 
(35, 49). This “pseudo-washout” can be observed in 
high-flow hemangiomas (50) and other non-hepatocyte-
containing lesions, which decreases the specificity of 
diagnosis of HCCs, including hypervascular intrahepatic 
cholangiocarcinomas (ICC) (47, 51, 52).
In the 2016 KSAR consensus meeting, in responses to 
the question “Which phase(s) would be appropriate for 
determining washout appearance?”, “PVP or TP” gained 
85.3% votes, while “PVP only” gained 14.7% votes. The 
reasons for this choice include: 1) inclusion of the TP would 
increase the diagnostic sensitivity for HCC, but it would not 
substantially decrease the positive predictive value,which 
might be a more suitable parameter in Korea, considering 
the high prevalence of HCC and low availability of DDLT 
as a treatment option (4); 2) in most cases, high-flow 
hemangiomas, which mimic HCCs on dynamic phase images 
(i.e., arterial hyperenhancement and pseudo-washout in the 
TP), can be ruled out using other MRI sequences (e.g., T2-
weighted [T2W] or diffusion-weighted [DW] imaging with 
an apparent diffusion coefficient map) (50, 53, 54); and 3) 
in patients with hypervascular ICCs, which mimic HCCs on 
gadoxetic acid-enhanced MR images, prognosis following 
treatment by the same method as that for equivalent-stage 
HCC has not been well established (55, 56). To sum up, the 
appropriate phase for detection of washout appearance on 
gadoxetic acid-enhanced MR images should be determined 
considering the inevitable trade-off between sensitivity 
and specificity in HCC diagnosis. Additionally, the role of 
ancillary features and effects on clinical outcomes should 
also be considered.
Consensus Statement
Washout appearance should be determined on either the 
PVP or TP of gadoxetic acid-enhanced MRI.
Sub-Centimeter-Sized HCC
The AASLD and EASL-EORTC guidelines do not allow 
imaging diagnosis of sub-centimeter-sized HCC. Instead of 
instantaneous diagnosis of sub-centimeter-sized lesions, 
these guidelines recommend augmented follow-up at short 
intervals of 3–4 months, as opposed to regular surveillance, 
typically at 6-month intervals. This recommendation is 
based on the belief that a majority of nodules of sizes < 1 
cm are unlikely to be HCCs (57). Although there are some 
contrary evidence (58-60), over 90% of arterial-enhancing 
lesions of sizes < 20 mm were found to be non-neoplastic 
both in patients with and without history of HCC (61, 62). 
In addition, the diagnostic performance of imaging studies 
for smaller HCCs is low. According to a recent meta-analysis, 
per-lesion sensitivity for diagnosis of HCCs of sizes < 1 cm 
was significantly lower compared to that for HCCs of sizes 
≥ 1 cm (CT, 31% vs. 82%, p < 0.001; MRI, 48% vs. 88%, p = 
0.02) (42, 63). Even when sub-centimeter-sized lesions are 
diagnosed on CT or MR images, it would be tricky to co-
localize them for intervention or surgery (64, 65).
In comparison with other imaging modalities, gadoxetic 
acid-enhanced MRI provides a greater opportunity for 
detection of small or early HCCs (13), which is supported by 
evidence that gadoxetic acid-enhanced MRI outperforms CT 
and ECCM-MRI in diagnosis of lesions of sizes < 1–2 cm (66-
69). Moreover, a significant proportion of sub-centimeter-
sized lesions detected by gadoxetic acid-enhanced MRI are 
likely to be or turn into HCC within a short time period 
(70, 71). In accordance with these new findings, several 
recent guidelines, including those of the KLCSG-NCC, JSH, 
APASL, and LI-RADS v2014, allow imaging diagnosis of sub-
centimeter-sized HCC. Given that the mainstay treatment 
for HCC in Korea is locoregional treatment rather than liver 
transplantation, detection of smaller lesions susceptible 
to locoregional treatment appears meaningful (72-75). 
Additionally, new diagnostic techniques, such as fusion 
of real-time ultrasonography (US) images with CT/MR 
or contrast-enhanced US images, have made it possible 
to accurately localize small lesions for local treatment 
(76), thus bridging the distance between gadoxetic acid-
enhanced liver MRI and optimal treatment.
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Despite the greater efficacy of gadoxetic acid-enhanced 
MRI in comparison with those of conventional imaging 
modalities for diagnosis of sub-centimeter-sized HCC, the 
diagnostic performance of gadoxetic acid-enhanced liver 
MRI alone is still unsatisfactory (63, 77). Recent studies 
have reported that inclusion of ancillary imaging features, 
including moderate hyperintensity on T2W imaging (T2WI), 
restricted diffusion, and hypointensity in the HBP, along 
with the typical vascular profile changes of HCC improves 
the diagnostic performance of gadoxetic acid-enhanced 
liver MRI in small HCCs (Fig. 3) (63, 71, 77-80). Therefore, 
typical vascular profile changes should not be relied on as 
the sole criteria for diagnosis of sub-centimeter-sized HCC. 
Besides, the clinical benefits of treatment of sub-
centimeter-sized lesions are yet to be proven. Although 
lesion size of 2 cm has been suggested as being indicative 
of aggressiveness and invasiveness in HCC (74, 81, 82), 
it is not clear whether the same may be extrapolated to 
sub-centimeter-sized lesions. Therefore, caution should 
be exercised in diagnosis of sub-centimeter-sized HCC, 
because the additional cost and possibility of false-positive 
diagnosis could offset its potential clinical benefits.
In the 2016 KSAR consensus meeting, the consensus 
levels for the following two statements were 86% and 98%, 
respectively.
Consensus Statements
1. Sub-centimeter-sized HCC may be diagnosed by 
gadoxetic acid-enhanced liver MRI by applying additional 
refined diagnostic criteria in addition to the typical vascular 
profile changes. 
2. Additional diagnostic criteria include ancillary 
Fig. 3. Sub-centimeter-sized HCC in 56-year-old man with chronic hepatitis B. 
Gadoxetic acid-enhanced MR image demonstrates 0.8-cm nodule (arrows) in right lobe of liver, adjacent to portal vein (A). Nodule exhibits 
arterial hyperenhancement, persistent hyperintensity during portal venous phase (B), and hypointensity during transitional (C), and 
hepatobiliary phases (D). Lesion (arrows) also exhibits other ancillary features, including intermediate hyperintensity on T2-weighted images (E), 
and restricted diffusion (F). Lesion was pathologically confirmed as HCC after hepatic resection. HCC = hepatocellular carcinoma
A B C
D E F
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MRI findings such as moderate hyperintensity on T2WI, 
restricted diffusion, and hypointensity in the HBP.
Nodules of Sizes Ranging from 1 to 2 cm
While some guidelines, including those of the EASL-EORTC 
and LI-RADS v2014, have provided different diagnostic 
criteria for nodules of sizes ranging from 1 to 2 cm and 
for those with sizes > 2 cm, other guidelines, including 
those of the AASLD, KLCSG-NCC, JSH, and APASL, have 
not. Because of the concern that nodules of sizes < 2 cm 
are more likely to be benign lesions than HCC (61, 62), 
guidelines such as those of the EASL-EORTC and LI-RADS 
v2014 have implemented stricter criteria for such lesions in 
order to maintain high diagnostic specificity. The previous 
version of the AASLD guidelines required coincidental 
positivity on two imaging modalities for lesions < 2 cm 
in size. However, since sequential use of a single imaging 
modality exhibits similar specificity as simultaneous 
imaging, with substantially reduced resource expenditure, 
this policy was discarded in the latest version of the AASLD 
guidelines (83, 84). Furthermore, the findings of recent 
meta-analyses revealed gadoxetic acid-enhanced MRI as 
exhibiting excellent diagnostic performance for lesions < 2 
cm in size (sensitivity, 79–95%; specificity, 89–92%) (69, 
85). Thus, in the era of gadoxetic acid-enhanced MRI, the 
necessity of the 2-cm cut-off appears to be diminishing.
In the 2016 KSAR consensus meeting, the following 
statement received 86% votes.
Consensus Statement
Nodules of sizes ranging from 1 to 2 cm and those of 
sizes > 2 cm do not require separate diagnostic criteria.
Non-Hypervascular Hypointense Nodules in the HPB
Non-hypervascular hypointense nodules in the HPB is an 
important issue with gadoxetic acid-enhanced MRI. Several 
studies have suggested that expression of organic anion 
transporting polypeptide 1B1/3 (OATP 1B1/3) decreases 
with tumor progression, which can be assessed using 
hepatocyte-specific MR contrast agents (36, 48, 86). Given 
that OATP 1B1/3 expression decreases prior to angiogenesis, 
hypointense HBP nodules appear prior to HCCs with typical 
hemodynamic hallmarks, which proves the feasibility of 
gadoxetic acid-enhanced MRI in detecting early HCC (41, 
48, 87, 88). Although the clinical impact of these non-
hypervascular HBP hypointense nodules in cirrhotic patients 
is not yet clearly defined, several papers reported that a 
substantial proportion of nonhypervascular HBP hypointense 
nodules (≥ 1 cm) were pathologically diagnosed as early 
HCCs followed by high-grade dysplastic nodules (HGDNs) (89, 
90), up to 30% of nodules were found to have transformed 
to typical hypervascular HCCs on follow-up imaging within 
3 years (89, 91-95); additionally, patients with non-
hypervascular HBP hypointense nodules exhibited shorter 
recurrence-free survival after radiofrequency ablation 
and lower overall survival after liver resection than those 
without (96, 97).
However, most guidelines, except JSH or APASL, do 
not recommend noninvasive imaging diagnosis of non-
hypervascular HBP hypointense nodules (2, 3) because of 
the considerable overlap in features between early HCCs 
and HGDNs as well as the very low specificity (41, 48, 89, 
98-101). Several ancillary features, including restricted 
diffusion, mild to moderate T2 hyperintensity, diameter > 
1.5 cm, and presence of fat, are useful for cross-sectional 
or longitudinal characterization of non-hypervascular HBP 
hypointense nodules (89, 90, 92, 102-107).
At present, management for patients with non-
hypervascular HBP hypointense nodules is controversial and 
includes several options, such as biopsy, intense follow-
up, and additional studies such as contrast-enhanced US 
(1, 99). Although non-hypervascular HBP hypointense 
nodules have a probability of transforming into malignant 
or premalignant nodules, they do not have to be treated as 
urgently as hypervascular HCCs (99, 108). A recent study 
demonstrated simultaneous resection of concomitant non-
hypervascular HBP nodules with typical hypervascular 
HCCs could provide significant benefit for recurrence-
free survival (109). However, another study reported only 
marginal survival benefit from resection of early HCCs 
(110). Therefore, further studies on management of non-
hypervascular HBP hypointensenodule are required.
In the 2016 KSAR consensus meeting, the following 
statements received 86% and 83% votes, respectively.
Consensus Statements
1. Non-hypervascular HBP hypointense nodules with mild 
to moderate T2 hyperintensity and/or restricted diffusion 
should be considered potentially malignant. 
2. Strategies for diagnosis and management of non-
hypervascular HBP hypointense nodules should vary 
according to previous or concomitant HCC.
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Capsular Appearance
Capsular appearance is defined by the LI-RADS guidelines 
v2014 as a “peripheral rim of smooth hyper-enhancement 
in the PVP or DP that unequivocally is thicker or more 
conspicuous than the rims surrounding background nodule” 
(5). Capsular appearance is more difficult to recognize with 
gadoxetic acid-enhanced MRI than with ECCM-enhanced 
MRI, because early gadoxetic acid uptake by hepatocytes 
leads to early appearance of strong liver parenchyma 
enhancement in the PVP and/or TP, which, in turn, obscures 
any capsular rim enhancement (35). Because of this 
difference in pharmacodynamics characteristics, capsular 
appearance should be defined differently on gadoxetic 
acid-enhanced and ECCM-enhanced MR images. In a recent 
pathologic correlation study, presence of a smooth dark 
rim in the HBP was found to exhibit greater correlation 
with presence of histologic capsule than with conventional 
capsular appearance on the PVP or TP (76.1% vs. 59.4%; 
p < 0.001) (Fig. 4) (111). This capsular appearance in the 
HBP corresponds to HBP hypointense rim, a new, but not 
major, ancillary feature favoring malignancy described in 
the LI-RADS v2014 lexicon (35). Capsular appearance has 
been presented as one of the major features of HCC in 
the LI-RADS and OPTN guidelines. However, most other 
current imaging-based diagnostic guidelines do not include 
capsular appearance as a major feature for HCC diagnosis 
mainly because of its lack of additional diagnostic value 
(18). Additionally, interobserver agreement on capsular 
appearance has been reported as being merely moderate (19).
In the 2016 KSAR consensus meeting, the statement that 
Fig. 4. HCC with hepatobiliary phase (HBP) capsule appearance in 59-year-old female hepatitis B virus carrier. 
A. 2.8-cm tumor (arrow) in right posterior hepatic section shows hyperenhancement in arterial phase. B-D. Tumor (arrows) becomes hypointense 
relative to liver from portal phase (B), to late portal phase (C), and to transitional phase (3 minutes) (D), and shows no conventional capsule 
appearance (peripheral rim of smooth hyperenhancement). Note that smooth hypointense rim (arrow) begins to appear in transitional phase. E. 
In HBP, smooth hypointense rim (arrow) clearly surrounds tumor. F. Surgical specimen revealed well-capsulated tumor (cut in half), which was 
confirmed as HCC with complete fibrous capsule on microscopic examination. HCC = hepatocellular carcinoma
A B C
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“capsular appearance is better considered an ancillary feature 
than a major feature for diagnosis of HCC” received 79.7% 
votes, while the following statement received 85.3% votes.
Consensus Statement
The definition of capsular appearance on gadoxetic acid-
enhanced MR images should be different from that on 
Fig. 5. Moderately differentiated HCC in 60-year-old man. 
2.1-cm-sized small hepatic nodule shows (arrows) isointensity during unenhanced T1-weighted image (A), arterial-phase (B), on portal venous 
and 3 minutes transitional-phase image (not shown) (C), and 20 minutes hepatobiliary-phase images after administration of gadoxetic acid (D). 
This lesion (arrows) is seen as hyperintense on single-shot echo-planar diffusion-weighed imaging at b = 800 sec/mm2 (E) and T2-weighted 
image (F). Surgical specimen revealed 2-cm, single nodular type HCC with Edmondson grade II (G). HCC = hepatocellular carcinoma
A B C
D E F
G
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ECCM-based MR images.
Ancillary Features
In view of the limitations of the current HCC diagnostic 
criteria, which rely on enhancement patterns, addition of 
a variety of ancillary features would be reasonable method 
for improving diagnostic accuracy for HCC. Because HCC on 
gadoxetic acid-enhanced MR images might exhibit different 
enhancement patterns from that on ECCM-enhanced MR 
images, other features apart from enhancement patterns 
could be important for diagnosis of HCC.
Although they are not specific for HCC, restricted diffusion 
and mild to moderate T2 hyperintensity are important 
ancillary features for differentiating between malignant and 
benign lesions (Fig. 5). However, the sensitivities of these 
features are not high because several well-differentiated 
HCCs and some small moderately-differentiated HCCs exhibit 
iso or hypointensity on T2W and DW images (36). Moreover, 
DW imaging for diagnosis of HCC presents additional issues. 
First, background fibrotic parenchyma frequently exhibit 
lower diffusivity than normal liver, thereby, reducing the 
lesion–liver contrast on DW images. Second, DW images 
are prone to spatial distortion and motion artifacts, which 
make reliable evaluation of hepatic lesions challenging, 
especially in the left lateral hepatic section, where artifacts 
due to cardiac motion are inevitable. Third, small HCCs 
and hemangiomas might exhibit overlapping DW signal 
intensities (112). For these reasons, the KSAR members 
could not reach consensus (74%) on the additional role of 
restricted diffusion and mild-moderate T2 hyperintensity as 
ancillary features for differentiating HCCs from premalignant 
nodules under typical circumstances; however, this criterion 
achieved consensus under special preconditions, including 
sub-centimeter-sized nodules with typical vascular profile 
changes (98%) and non-hypervascular HBP hypointense 
nodules (86.4%) in high-risk populations.
The LI-RADS guidelines are the only ones to incorporate 
a variety of ancillary features that might favor HCC or 
benign nodules by a more detailed evaluation of imaging 
findings (9). The LI-RADS v2014 ancillary features that 
might favor malignancy include HBP and TP hypointensity, 
mild to moderate T2 hyperintensity, restricted diffusion, 
distinctive rim, corona enhancement, mosaic and nodule-
in-nodule architecture, intra-lesional fat, lesional iron and 
fat sparing, blood products, and diameter increase less than 
the threshold (5). Of these features, distinctive rim, coronal 
enhancement, mosaic and nodule-in-nodule architecture, 
and intra-lesional fat are considered as specifically favoring 
HCC over malignancies (5). These ancillary features in the 
LI-RADS guidelines are intended to modify the likelihood of 
diagnosis of HCC but not to upgrade HCC category to LR5 
(definitely HCC) without any weighted value on individual 
features. However, since these ancillary features vary in 
frequency and importance and are challenging to detect by 
gadoxetic acid-enhanced MRI, the KSAR members reached 
an 86% consensus for the following statement.
Consensus Statement
The impact of ancillary features on diagnosis of HCC 
should be clearly defined, and these features should be 
adapted for gadoxetic acid-enhanced MRI.
CONCLUSION
Despite its better diagnostic performance for HCC in 
comparison with other imaging modalities, most current 
guidelines have neither accepted gadoxetic acid-enhanced 
MRI as a mainstream diagnostic algorithm nor defined 
standard criteria for diagnosis of HCC by this method. The 
2016 KSAR meeting reached consensus on several issues 
of debate from the radiologists’ point of view, based on 
routine clinical practices. Although several challenges 
remain in terms of optimization and standardization, these 
consensus recommendations might serve as useful tools to 
ensure more standardized diagnosis of HCC by gadoxetic 
acid-enhanced MRI. 
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